|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Galectin-3 and IL-33/ST2 axis roles and interplay in dietinduced steatohepatitis显示文摘Immune reactivity and chronic low-grade inflammation(metaflammation) play an important role in the pathogenesis of obesity-associated metabolic disorders, including type 2 diabetes and nonalcoholic fatty liver disease(NAFLD), a spectrum of diseases that include liver steatosis, nonalcoholic steatohepatitis(NASH), fibrosis, and cirrhosis. Increased adiposity and insulin resistance contribute to the progression from hepatic steatosis to NASH and fibrosis through the development of proinflammatory and profibrotic processes in the liver, including increased hepatic infiltration of innate and adaptive immune cells, altered balance of cytokines and chemokines, increased reactive oxygen species generation and hepatocellular death. Experimental models of dietary-induced NAFLD/NASH in mice on different genetic backgrounds or knockout mice with different immune reactivity are used for elucidating the pathogenesis of NASH and liver fibrosis. Galectin-3(Gal-3), a unique chimera-type β-galactoside-binding protein of the galectin family has a regulatory role in immunometabolism and fibrogenesis. Mice deficient in Gal-3 develop pronounced adiposity, hyperglycemia and hepatic steatosis, as well as attenuated liver inflammation and fibrosis when fed an obesogenic high-fat diet. Interleukin(IL)-33, a member of the IL-1 cytokine family, mediates its effects through the ST receptor, which is present on immune and nonimmune cells and participates in immunometabolic and fibrotic disorders. Recent evidence, including our own data, suggests a protective role for the IL-33/IL-33R(ST2) signaling pathway in obesity, adipose tissue inflammation and atherosclerosis, but a profibrotic role in NASH development. The link between Gal-3 and soluble ST2 in myocardial fibrosis and heart failure progression has been demonstrated and we have recently shown that Gal-3 and the IL-33/ST2 pathway interact and both have a profibrotic role in diet-induced NASH. This review discusses the current evidence on the roles of Gal-3 and the IL-33/ST2 pathway and their interplay in obesity-associated hepatic inflammation and fibrogenesis that may be of interest in the development of therapeutic interventions to prevent and/or reverse obesity-associated hepatic inflammation and fibrosis. | Nada Pejnovic Ilija Jeftic Nemanja Jovicic Nebojsa Arsenijevic Miodrag L Lukic | 2016 | World Journal of Gastroenterology2016，22，44： | 9 |
| 2 | Metabolic syndrome attenuates ulcerative colitis: Correlation with interleukin-10 and galectin-3 expression显示文摘BACKGROUND Ulcerative colitis(UC)is a chronic disease characterized by inflammation of intestinal epithelium,primarily of the colon.An increasing prevalence of metabolic syndrome(MetS)in patients with UC has been documented recently.Still,there is no evidence that MetS alters the course of the UC.AIM To test the influence of the MetS on the severity of UC and the local and systemic immune status.METHODS Eighty nine patients with de novo histologically confirmed UC were divided in two groups,according to ATP III criteria:Group without MetS(no MetS)and group with MetS.RESULTS Clinically and histologically milder disease with higher serum level of immunosuppressive cytokine interleukin-10(IL-10)and fecal content of Galectin-3(Gal-3)was observed in subjects with UC and MetS,compared to subjects suffering from UC only.This was accompanied with predomination of IL-10 over pro-inflammatory cytokines tumor necrosis factorα(TNF-α),interleukin-6(IL-6),and interleukin-17(IL-17)in the sera as well as Gal-3 over TNF-αand IL-17 in feces of UC patients with MetS.Further,the patients with both conditions(UC and MetS)had higher percentage of IL-10 producing and Gal-3 expressing innate and acquired immune cells in lamina propria.CONCLUSION Local dominance of Gal-3 and IL-10 over pro-inflammatory mediators in patients with MetS may present a mechanism for limiting the inflammatory process and subsequent tissue damage in UC. | Marina Jovanovic Bojana Simovic Markovic Nevena Gajovic Milena Jurisevic Aleksandar Djukic Ivan Jovanovic Nebojsa Arsenijevic Aleksandra Lukic Natasa Zdravkovic | 2019 | World Journal of Gastroenterology2019，25，43： | 5 |
| 3 | Interleukin‐33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells显示文摘 | Ivan P. Jovanovic Nada N. Pejnovic Gordana D. Radosavljevic Jelena M. Pantic Marija Z. Milovanovic Nebojsa N. Arsenijevic Miodrag L. Lukic | 2014 | Int. J. Cancer2014，，： | 2 |
| 4 | ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma显示文摘 | Ivan Jovanovic Gordana Radosavljevic Maja Mitrovic Vanda Lisnic Juranic Andrew N. J. McKenzie Nebojsa Arsenijevic Stipan Jonjic Miodrag L. Lukic | 2011 | Eur. J. Immunol2011，，： | 2 |
| 5 | IL-33/ST2 axis in innate and acquired immunity to tumors显示文摘 | Ivan P. Jovanovic Nada N. Pejnovic Gordana D. Radosavljevic Nebojsa N. Arsenijevic Miodrag L. Lukic | 2012 | OncoImmunology2012，，： | 2 |
| 6 | The roles of Galectin-3 in autoimmunity and tumor progression显示文摘 | Gordana Radosavljevic Vladislav Volarevic Ivan Jovanovic Marija Milovanovic Nada Pejnovic Nebojsa Arsenijevic Daniel Hsu Miodrag Lukic | 2012 | Immunologic Research2012，，1： | 2 |
| 7 | Retinal stem cells promising candidates for retina transplantation 显示文摘 | Djojosubrnto MW Arsenijevic Y | 2008 | Cell Tissue Res2008，1，： | 1 |
| 8 | Lipoprotein lipase and endothelial lipase expression in mouse brain:regional distribution and selective induction following kainic acid-induced lesion and focal cerebral ischemia 显示文摘 | Paradis E Clavel S Julien P Murthy MRV de Bilbao F Arsenijevic D | 2004 | Neurobiol Disease2004，15，2： | 1 |
| 9 | Prognostic signifi- cance of co-overexpression of bel-2 and c-erbB-2/neu in uterine cervix carcinomas and premalignant lesions 显示文摘 | Protrka Z Arsenijevic S Arsenijevic P et ai | 2012 | Med Glas ( Zeni- ca)2012，9，2： | 1 |
| 10 | Effects of nitrogen nutrition on photosynthesis in Cd-treated sunflower plants显示文摘 | Pankovic D Plesnicar M Arsenijevic Maksimovic I | 2000 | Annals of Botany2000，86，4： | 1 |
| 11 | Disruption of the uncoupling protein-2gene in mice reveals a role in immunity and reactive oxygen species production显示文摘 | Arsenijevic D Onuma H Pecqueur C | 2000 | Nat Genet2000，26，4： | 1 |
| 12 | Insulin-like growth factor-I is necessary for neural stem cell proliferation and demonstrates distinct actions of epidermal growth factor and fibroblast growth factor-2显示文摘 | Arsenijevic Y Weiss S Schneider B | 2001 | J Neurosci2001，21，18： | 1 |
| 13 | Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis显示文摘 | Vladislav Volarevic Ahmed Al-Qahtani Nebojsa Arsenijevic Sladjana Pajovic Miodrag L. Lukic | 2009 | Autoimmunity2009，，4： | 1 |
| 14 | A role for the POU-Ⅲ transcription factor Brn-4 in the regulation of striatal neuron precursor differentiation显示文摘 | Shimazaki T Arsenijevic Y Ryan AK | 1999 | EMBO J1999，18，2： | 1 |
| 15 | Isolation of multipotent neural precursors residing in the cortex of the adult human brain显示文摘 | ARSENIJEVIC Y VILLEMURE JG BRUNET JF | 2001 | Exp Neurol2001，170，1： | 1 |
| 16 | A role for the POU-Ⅲ transcription factor Brn-4 in the regulation of striatal neuron precursor differentiation显示文摘 | Shimazaki T Arsenijevic Y Ryan AK | 1999 | EMBO J1999，18，2： | 1 |
| 17 | Epidermal growth factor is a neuronal differentiation factor for retinal stern cells in vitro显示文摘 | Angnieux B Schorderet DF Arsenijevic Y | 2006 | Stem Cells2006，3，： | 1 |
| 18 | A role for the POU-Ⅲ transcription factor Brn-4 in the regulation of striatal neuron precursor differentiation 显示文摘 | Shimazaki T Arsenijevic Y Ryan AK | 1999 | EMBO J1999，18，2： | 1 |
| 19 | Insulin-like growth factor-I is necessary for neural stem cell proliferation and demonstrates distinct actions of epidermal growth factor and fibroblast growth factor-2显示文摘 | Arsenijevic Y Weiss S Schneider B | 2001 | J Neurosci2001，21，18： | 1 |
| 20 | Mammalian neural stem cell renewal显示文摘 | ARSENIJEVIC Y | 2003 | Mol Neuro2003，27，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员